A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY／Japan Moves toward Affiliation with PIC/S
April 23, 2007
- COMMENTARY／India Attracts Increasing Attention of Japanese Pharmas
April 16, 2007
- COMMENTARY：Growing Market for Biopharmaceuticals
April 2, 2007
- Japanese Pharma Companies' Licensing Policy: 1 （2） Takeda Pharmaceutical Co., Ltd.
March 26, 2007
- Comentary
March 26, 2007
- Japanese Pharma Companies' Licensing Policy: 1 （1） Takeda Pharmaceutical Co., Ltd.
March 26, 2007
- Future of the Life Sciences Industries: Strategies for Success in 2015
March 19, 2007
- 3 Advantages of Gov't-Private Sector Dialogue Industry Needs to Continuously Present Proposals
February 19, 2007
- Breakthrough Pipelines of Japanese Pharma Companies Keiji Nakamura, Ph. D. Pharma Forum Institute, Kamakura 248-0026
February 12, 2007
- Present and Future of Pharmaceutical Companies in Japan -1- -Prospects for 2001 Analyzed Based on Korosho's Vision for the Pharmaceutical Industry-
January 22, 2007
- Present and Future of Pharmaceutical Companies in Japan -2- -Prospects for 2001 Analyzed Based on Korosho's Vision for the Pharmaceutical Industry-
January 22, 2007
- COMMENTARY 4 articles
December 25, 2006
- Reform Promotion Council to Propose Reference Price System Again
December 11, 2006
- COMMENTARY Major GE Houses Working to Increase Business with Wholesalers
November 13, 2006
- COMMENTARY New Promotion Code to Go into Effect Next January
October 30, 2006
- 70% of People 40 Years or Older Have Pain in Joints, Lower Back: Survey by Stryker
October 23, 2006
- Surveys by JMA, FTC Provide Evidence for Discussions on Generics
October 16, 2006
- COMMENTARY／Original and Generic Makers Should Cooperate for Stable Supply
September 11, 2006
- COMMENTARY Government Increases Efforts to Promote Clinical Research
September 4, 2006
- TOPICS 2 articles
August 28, 2006
ページ
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…